BTSG (BTSG) Stock Analysis

Verdict: HOLD

Specialty pharmacy expansion drives double-digit top-line growth, but razor-thin 3.3% operating margins and PE overhang cap upside.

Investment score: 56/100

BrightSpring Health demonstrates solid 19.9% top-line expansion and positive cash flow momentum, but elevated debt levels and major PE insider selling warrant patience before building new long positions.

Peers

PeerP/EP/BP/SEV/EBITDAROIC %Net margin %
DGX25.903.622.3616.450.09
LH26.663.081.8515.450.07
GH-50.11-103.6519.84-58.65-0.38
LH26.663.081.8515.450.07
DVA16.67-16.410.898.160.06

View the full interactive analysis